Figlin RA - Search Results

1

Hutson TE, Figlin RA. Hutson TE, et al. Among authors: figlin ra. Cancer J. 2007 Sep-Oct;13(5):282-6. doi: 10.1097/PPO.0b013e318156fe69. Cancer J. 2007. PMID: 17921725 Review.

2

Renal cell carcinoma: basic biology and clinical behavior.

Franklin JR, Figlin R, Belldegrun A. Franklin JR, et al. Semin Urol Oncol. 1996 Nov;14(4):208-15. Semin Urol Oncol. 1996. PMID: 8946619 Review.

3

Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience.

Franklin JR, Figlin R, Rauch J, Gitlitz B, Belldegrun A. Franklin JR, et al. Semin Urol Oncol. 1996 Nov;14(4):230-6. Semin Urol Oncol. 1996. PMID: 8946623

4

Renal cell carcinoma: management of advanced disease.

Figlin RA. Figlin RA. J Urol. 1999 Feb;161(2):381-6; discussion 386-7. doi: 10.1016/s0022-5347(01)61897-4. J Urol. 1999. PMID: 9915408 Review.

5

Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma.

Belldegrun A, Shvarts O, Figlin RA. Belldegrun A, et al. Among authors: figlin ra. Cancer J Sci Am. 2000 Feb;6 Suppl 1:S88-92. Cancer J Sci Am. 2000. PMID: 10685666

6

Infusional interleukin-2 and 5-fluorouracil with subcutaneous interferon-alpha for the treatment of patients with advanced renal cell carcinoma: a southwest oncology group Phase II study.

Elias L, Lew D, Figlin RA, Flanigan RC, Thompson ME, Triozzi PL, Belt RJ, Wood DP Jr, Rivkin SE, David E. Elias L, et al. Among authors: figlin ra. Cancer. 2000 Aug 1;89(3):597-603. Cancer. 2000. PMID: 10931459 Clinical Trial.

7

Treatment of metastatic renal cell carcinoma with high-dose bolus interleukin-2 in a non-intensive care unit: an analysis of 124 consecutively treated patients.

Gitlitz BJ, Hoffman DM, Moldawer N, Belldegrun A, Figlin RA. Gitlitz BJ, et al. Among authors: figlin ra. Cancer J. 2001 Mar-Apr;7(2):112-20. Cancer J. 2001. PMID: 11324764 Clinical Trial.

8

Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.

Tso CL, Zisman A, Pantuck A, Calilliw R, Hernandez JM, Paik S, Nguyen D, Gitlitz B, Shintaku PI, de Kernion J, Figlin R, Belldegrun A. Tso CL, et al. Cancer Res. 2001 Nov 1;61(21):7925-33. Cancer Res. 2001. PMID: 11691814

9

Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials.

Leibovich BC, Han KR, Bui MH, Pantuck AJ, Dorey FJ, Figlin RA, Belldegrun A. Leibovich BC, et al. Among authors: figlin ra. Cancer. 2003 Dec 15;98(12):2566-75. doi: 10.1002/cncr.11851. Cancer. 2003. PMID: 14669275 Free article.

10

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.

Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI. Motzer RJ, et al. Among authors: figlin ra. J Clin Oncol. 2006 Jan 1;24(1):16-24. doi: 10.1200/JCO.2005.02.2574. Epub 2005 Dec 5. J Clin Oncol. 2006. PMID: 16330672 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

381 results

Search Page

Filters